Economic burden of HPV9-related diseases

a real-world cost analysis from Italy

F. S. Mennini, Gianluca Fabiano, G. Favato, P. Sciattella, P. Bonanni, C. Pinto, A. Marcellusi

Research output: Contribution to journalArticle

Abstract

Introduction: The objectives of this study were to estimate the economic burden of HPV in Italy, accounting for total direct medical costs associated with nine major HPV-related diseases, and to provide a measure of the burden attributable to HPV 6, 11, 16, 18, 31, 33, 45, 52, 58 infections. Methods: A cost-of-illness incidence-based model was developed to estimate the incidences and costs of invasive cervical cancer, cervical dysplasia, cancer of the vulva, vagina, anus, penis, oropharyngeal, anogenital warts, and recurrent respiratory papillomatosis (RRP) in the context of the Italian National Health System (NHS). We used data from hospital discharge records (HDRs) of an Italian region and conducted a systematic literature review to estimate the lifetime cost per case, the number of incident cases, the prevalence of HPV9 types. Costs of therapeutic options not included in the diagnosis-related group (DRG) tariffs were estimated through a scenario analysis. Results: In 2018, the total annual direct costs were €542.7 million, with a range of €346.7–€782.0 million. These costs could increase considering innovative therapies for cancer treatment (range €16.2–€37.5 million). The fraction attributable to the HPV9 genotypes without innovative cancers treatment was €329.5 million, accounting for 61% of the total annual burden of HPV-related diseases in Italy. Of this amount, €135.9 million (41%) was related to men, accounting for 64% of the costs associated with non-cervical conditions. Conclusions: The infections by HPV9 strains and the economic burden of non-cervical HPV-related diseases in men were found to be the main drivers of direct costs.

Original languageEnglish
JournalEuropean Journal of Health Economics
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Italy
Economics
Costs and Cost Analysis
Uterine Cervical Neoplasms
Vaginal Neoplasms
Vulvar Neoplasms
Uterine Cervical Dysplasia
Human papillomavirus 11
Human papillomavirus 6
Investigational Therapies
Cost of Illness
Warts
Costs
Cost analysis
Burden
Hospital Records
Diagnosis-Related Groups
Incidence
Penis
Anal Canal

Keywords

  • Burden of disease
  • Human papillomavirus
  • Italy
  • Real world

ASJC Scopus subject areas

  • Economics, Econometrics and Finance (miscellaneous)
  • Health Policy

Cite this

Economic burden of HPV9-related diseases : a real-world cost analysis from Italy. / Mennini, F. S.; Fabiano, Gianluca; Favato, G.; Sciattella, P.; Bonanni, P.; Pinto, C.; Marcellusi, A.

In: European Journal of Health Economics, 01.01.2019.

Research output: Contribution to journalArticle

Mennini, F. S. ; Fabiano, Gianluca ; Favato, G. ; Sciattella, P. ; Bonanni, P. ; Pinto, C. ; Marcellusi, A. / Economic burden of HPV9-related diseases : a real-world cost analysis from Italy. In: European Journal of Health Economics. 2019.
@article{7a41c1795f314d7d9c3713e51163136d,
title = "Economic burden of HPV9-related diseases: a real-world cost analysis from Italy",
abstract = "Introduction: The objectives of this study were to estimate the economic burden of HPV in Italy, accounting for total direct medical costs associated with nine major HPV-related diseases, and to provide a measure of the burden attributable to HPV 6, 11, 16, 18, 31, 33, 45, 52, 58 infections. Methods: A cost-of-illness incidence-based model was developed to estimate the incidences and costs of invasive cervical cancer, cervical dysplasia, cancer of the vulva, vagina, anus, penis, oropharyngeal, anogenital warts, and recurrent respiratory papillomatosis (RRP) in the context of the Italian National Health System (NHS). We used data from hospital discharge records (HDRs) of an Italian region and conducted a systematic literature review to estimate the lifetime cost per case, the number of incident cases, the prevalence of HPV9 types. Costs of therapeutic options not included in the diagnosis-related group (DRG) tariffs were estimated through a scenario analysis. Results: In 2018, the total annual direct costs were €542.7 million, with a range of €346.7–€782.0 million. These costs could increase considering innovative therapies for cancer treatment (range €16.2–€37.5 million). The fraction attributable to the HPV9 genotypes without innovative cancers treatment was €329.5 million, accounting for 61{\%} of the total annual burden of HPV-related diseases in Italy. Of this amount, €135.9 million (41{\%}) was related to men, accounting for 64{\%} of the costs associated with non-cervical conditions. Conclusions: The infections by HPV9 strains and the economic burden of non-cervical HPV-related diseases in men were found to be the main drivers of direct costs.",
keywords = "Burden of disease, Human papillomavirus, Italy, Real world",
author = "Mennini, {F. S.} and Gianluca Fabiano and G. Favato and P. Sciattella and P. Bonanni and C. Pinto and A. Marcellusi",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s10198-019-01044-3",
language = "English",
journal = "European Journal of Health Economics",
issn = "1618-7598",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Economic burden of HPV9-related diseases

T2 - a real-world cost analysis from Italy

AU - Mennini, F. S.

AU - Fabiano, Gianluca

AU - Favato, G.

AU - Sciattella, P.

AU - Bonanni, P.

AU - Pinto, C.

AU - Marcellusi, A.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Introduction: The objectives of this study were to estimate the economic burden of HPV in Italy, accounting for total direct medical costs associated with nine major HPV-related diseases, and to provide a measure of the burden attributable to HPV 6, 11, 16, 18, 31, 33, 45, 52, 58 infections. Methods: A cost-of-illness incidence-based model was developed to estimate the incidences and costs of invasive cervical cancer, cervical dysplasia, cancer of the vulva, vagina, anus, penis, oropharyngeal, anogenital warts, and recurrent respiratory papillomatosis (RRP) in the context of the Italian National Health System (NHS). We used data from hospital discharge records (HDRs) of an Italian region and conducted a systematic literature review to estimate the lifetime cost per case, the number of incident cases, the prevalence of HPV9 types. Costs of therapeutic options not included in the diagnosis-related group (DRG) tariffs were estimated through a scenario analysis. Results: In 2018, the total annual direct costs were €542.7 million, with a range of €346.7–€782.0 million. These costs could increase considering innovative therapies for cancer treatment (range €16.2–€37.5 million). The fraction attributable to the HPV9 genotypes without innovative cancers treatment was €329.5 million, accounting for 61% of the total annual burden of HPV-related diseases in Italy. Of this amount, €135.9 million (41%) was related to men, accounting for 64% of the costs associated with non-cervical conditions. Conclusions: The infections by HPV9 strains and the economic burden of non-cervical HPV-related diseases in men were found to be the main drivers of direct costs.

AB - Introduction: The objectives of this study were to estimate the economic burden of HPV in Italy, accounting for total direct medical costs associated with nine major HPV-related diseases, and to provide a measure of the burden attributable to HPV 6, 11, 16, 18, 31, 33, 45, 52, 58 infections. Methods: A cost-of-illness incidence-based model was developed to estimate the incidences and costs of invasive cervical cancer, cervical dysplasia, cancer of the vulva, vagina, anus, penis, oropharyngeal, anogenital warts, and recurrent respiratory papillomatosis (RRP) in the context of the Italian National Health System (NHS). We used data from hospital discharge records (HDRs) of an Italian region and conducted a systematic literature review to estimate the lifetime cost per case, the number of incident cases, the prevalence of HPV9 types. Costs of therapeutic options not included in the diagnosis-related group (DRG) tariffs were estimated through a scenario analysis. Results: In 2018, the total annual direct costs were €542.7 million, with a range of €346.7–€782.0 million. These costs could increase considering innovative therapies for cancer treatment (range €16.2–€37.5 million). The fraction attributable to the HPV9 genotypes without innovative cancers treatment was €329.5 million, accounting for 61% of the total annual burden of HPV-related diseases in Italy. Of this amount, €135.9 million (41%) was related to men, accounting for 64% of the costs associated with non-cervical conditions. Conclusions: The infections by HPV9 strains and the economic burden of non-cervical HPV-related diseases in men were found to be the main drivers of direct costs.

KW - Burden of disease

KW - Human papillomavirus

KW - Italy

KW - Real world

UR - http://www.scopus.com/inward/record.url?scp=85063204957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063204957&partnerID=8YFLogxK

U2 - 10.1007/s10198-019-01044-3

DO - 10.1007/s10198-019-01044-3

M3 - Article

JO - European Journal of Health Economics

JF - European Journal of Health Economics

SN - 1618-7598

ER -